Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Wilson Therapeutics initiates phase III trial of WTX-101 for Wilson's disease

Feb. 19, 2018

Genethon begins trial of gene therapy for Crigler-Najjar Syndrome

Feb. 16, 2018

Xeris completes two phase III studies of its ready-to-use glucagon rescue pen

Feb. 16, 2018

Miglustat stabilizes ATB-200 in the circulation of Pompe disease patients

Feb. 16, 2018

FDA accepts Shire's sBLA for the use of Cinryze in children

Feb. 16, 2018

FDA approves Makena subcutaneous atuoinjector

Feb. 16, 2018

Somatic and neurological effects seen with AGT-181 in patients with MPS type I

Feb. 16, 2018

Boehringer Ingelheim Pharma & Co. patents GOAT inhibitors

Feb. 15, 2018

Combined delivery of CLN1 gene therapy proven to extend lifespan in INCL mice

Feb. 15, 2018

Researchers develop Drosophila model of multiple sulfatase deficiency

Feb. 14, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...